Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
NTHI
4576
NeOnc Technologies
NTHI
$86.1M
| $75.7K | ﹤0.01% |
9,151
+8,982
| +5,315% | +$84.2K |
2025 Q3
1 quarter
|
|
|
RDNW
4577
RideNow Group
RDNW
$210M
| $75.3K | ﹤0.01% |
+16,967
| New | +$79.3K |
2025 Q4
0 quarters
|
|
|
NFGC
4578
New Found Gold
NFGC
$623M
| $75.1K | ﹤0.01% |
+25,300
| New | +$62.1K |
2025 Q4
0 quarters
|
|
4579
FT Vest US Equity Buffer ETF May
FMAY
$1.48B
| $74.7K | ﹤0.01% |
1,397
-2,452
| -64% | -$129K |
2024 Q3
5 quarters
|
|
|
IMA
4580
ImageneBio Inc
IMA
$52.2M
| $74.5K | ﹤0.01% |
10,797
+6,810
| +171% | +$50.5K |
2022 Q1
15 quarters
|
|
|
ZAUG
4581
Innovator Equity Defined Protection ETF - 1 Yr August
ZAUG
$164M
| $74.4K | ﹤0.01% |
2,784
| – | – |
2024 Q3
5 quarters
|
|
4582
Skillsoft
SKIL
$52M
| $74.3K | ﹤0.01% |
7,986
+1,696
| +27% | +$18.9K |
2022 Q1
15 quarters
|
|
4583
Biomea Fusion
BMEA
$92.1M
| $73.2K | ﹤0.01% |
59,013
+55,790
| +1,731% | +$78.1K |
2022 Q1
15 quarters
|
|
4584
CALL
RELX
RELX
$58.1B
| $72.8K | ﹤0.01% |
+1,800
| New | +$76.8K |
2025 Q4
0 quarters
|
|
4585
Rapid Micro Biosystems
RPID
$46.1M
| $72.1K | ﹤0.01% |
+24,859
| New | +$86.3K |
2025 Q4
0 quarters
|
|
4586
iShares US Medical Devices ETF
IHI
$3.45B
| $71.6K | ﹤0.01% |
1,152
-2,058
| -64% | -$127K |
2020 Q2
22 quarters
|
|
4587
Mammoth Energy Services
TUSK
$135M
| $70.4K | ﹤0.01% |
38,064
-21,205
| -36% | -$42.8K |
2021 Q1
19 quarters
|
|
4588
Empire Petroleum
EP
$109M
| $69.9K | ﹤0.01% |
22,982
+1,781
| +8% | +$5.98K |
2022 Q2
14 quarters
|
|
|
ZJUN
4589
Innovator Equity Defined Protection ETF - 1 Yr June
ZJUN
$158M
| $69.8K | ﹤0.01% |
2,601
-3,082
| -54% | -$82.1K |
2025 Q3
1 quarter
|
|
4590
Red Robin
RRGB
$150M
| $69.5K | ﹤0.01% |
17,159
+14,146
| +469% | +$71K |
2024 Q3
5 quarters
|
|
4591
Pyxis Oncology
PYXS
$178M
| $69.4K | ﹤0.01% |
60,385
+57,424
| +1,939% | +$203K |
2024 Q2
6 quarters
|
|
4592
Innovator US Equity Power Buffer ETF March
PMAR
$748M
| $69.3K | ﹤0.01% |
1,542
-401
| -21% | -$17.8K |
2025 Q3
1 quarter
|
|
4593
Travelzoo
TZOO
$53.2M
| $69.3K | ﹤0.01% |
9,731
+734
| +8% | +$5.94K |
2024 Q3
5 quarters
|
|
4594
Xtrackers MSCI Japan Hedged Equity ETF
DBJP
$738M
| $69.1K | ﹤0.01% |
+730
| New | +$66.8K |
2025 Q4
0 quarters
|
|
4595
Vanguard FTSE All-World ex-US ETF
VEU
$68.8B
| $68.8K | ﹤0.01% |
935
-10,200
| -92% | -$742K |
2022 Q4
12 quarters
|
|
|
SVCO
4596
Silvaco Group
SVCO
$310M
| $68.5K | ﹤0.01% |
16,908
+5,867
| +53% | +$29.1K |
2024 Q3
5 quarters
|
|
4597
Innovator Equity Defined Protection ETF - 2 Yr to July 2027
TJUL
$116M
| $67.1K | ﹤0.01% |
+2,268
| New | +$66.8K |
2025 Q4
0 quarters
|
|
4598
iShares iBonds Dec 2029 Term Corporate ETF
IBDU
$3.95B
| $66.7K | ﹤0.01% |
+2,850
| New | +$66.8K |
2025 Q4
0 quarters
|
|
4599
MacroGenics
MGNX
$228M
| $66.6K | ﹤0.01% |
41,350
+2,044
| +5% | +$3.21K |
2019 Q1
27 quarters
|
|
4600
iShares iBonds Dec 2027 Term Corporate ETF
IBDS
$3.9B
| $66.4K | ﹤0.01% |
2,733
| – | – |
2024 Q1
7 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.